Something significant is happening in the health and wellness side of network marketing, and it deserves a serious look.

Over the past twelve months, Herbalife has gone on one of the most aggressive acquisition sprees in its 45-year history. The company has spent over $200 million acquiring technology and science companies whose entire purpose is to do one thing: prove that their products work on each individual customer using biological data.

That is not the way Herbalife has operated for most of its existence. It is, however, exactly the way a smaller Scandinavian company called Zinzino has operated since 2012.

The fact that Herbalife is now spending nine figures to build what Zinzino built organically is one of the most telling signals this industry has produced in years. This article breaks down what Herbalife is building, what Zinzino already has, how they compare, and what it means for anyone in this profession.

What Herbalife Has Been Buying

The acquisition trail starts in March 2025 when Herbalife announced it was purchasing assets from three companies simultaneously.

The first was Pro2col, a digital health and wellness application company whose platform uses individual biometrics to deliver personalized nutrition recommendations and tailored health and longevity protocols. The second was Link BioSciences, a Texas-based manufacturing company that uses proprietary technology to analyze biometrics, biomarkers, lifestyle data, and DNA to formulate personalized nutritional supplements. The third was Pruvit Ventures, a ketone products company acquired to expand Herbalife’s product range during the transition period. The total cost for these three acquisitions was approximately $25 to $30 million with additional performance-based payments possible.

Then in March 2026, Herbalife announced the acquisition of assets from Bioniq, a UK-based company that builds personalized supplement formulas using a patented product personalization engine, an individual’s health background, and a proprietary database of biomarkers. The Bioniq deal carries a purchase price of $55 million paid over five years, with up to $95 million in additional contingent payments based on future performance. Herbalife also obtained a call option on Bioniq LAB, a separate platform focused on small molecules and peptides.

The strategic logic connecting all of these acquisitions is identical. Pro2col collects individual health data through a digital app. Link BioSciences analyzes that data and uses it to manufacture personalized supplements. Bioniq adds a sophisticated biomarker-based personalization engine and a proprietary database built from hundreds of thousands of individual supplement formulations. Together, these acquisitions build a system where a customer’s supplement formula is not chosen from a catalog but designed specifically for their biology.

Herbalife CEO Stephan Gratziani described the vision directly: “The future of health and wellness is becoming more personalized and informed by data.”

On top of this, Cristiano Ronaldo, Herbalife’s long-time global nutrition partner, invested $7.5 million for a 10% equity stake in HBL Pro2col Software, the subsidiary housing the personalized technology platform. He is also a Bioniq shareholder. His financial involvement adds celebrity credibility that is harder to dismiss than a standard endorsement deal.

What Zinzino Already Has

While Herbalife is assembling its personalized nutrition platform through acquisitions, Zinzino has been operating one since 2012.

Founded in Norway in 2005 and now publicly listed on the Nasdaq First North Premier Growth Market in Scandinavia, Zinzino built its entire business model around what it calls test-based, personalized nutrition. The framework is straightforward: customers take a home blood test before starting any supplements, receive individualized results, follow a supplement protocol based on those results, and retest every four months to see documented proof that the products are working in their body.

The flagship product is BalanceOil, an omega-3 supplement formulated to address the omega-6 to omega-3 imbalance that Zinzino identifies in the majority of customers who test. The BalanceTest measures 11 fatty acids in the blood and generates six different health markers. Every test is administered and analyzed by Vitas, an independent, GMP-certified chemical analysis laboratory described as the world leader in dried blood spot testing.

That word, independent, matters. Zinzino does not analyze its own test results. A third party does. That distinction is a core part of the credibility argument Zinzino makes to customers and distributors.

Since integrating testing into its business in 2012, Zinzino has conducted over one million BalanceTests globally and now holds the world’s largest database of dried blood spot samples. The company has since expanded its testing portfolio beyond omega fatty acids to include a Vitamin D test, an HbA1c blood sugar test, and a Gut Health test launched in late 2025 that measures tryptophan-derived metabolites through blood rather than the stool-based testing most gut health competitors use.

The Science Question: How Do the Models Compare?

Both Herbalife and Zinzino are now operating in the same broad space: using biological data to personalize nutrition recommendations. But the architecture of their approaches is meaningfully different.

Zinzino’s model is built around a relatively focused set of measurable biomarkers. It starts with the omega-6 to omega-3 ratio because that is a well-documented, scientifically validated marker with clear nutritional interventions. The retest mechanism gives customers documented before-and-after evidence that is independently verified. The simplicity is a feature, not a limitation. Customers understand what was measured, what was found, what they took, and whether it worked. That is a clean, defensible scientific story.

Bioniq’s model, which Herbalife is now integrating, draws on a broader biomarker database to generate more comprehensive personalized formulas. The personalization engine incorporates a wider range of individual health background data and has created unique formulations for hundreds of thousands of users. The ambition is larger in scope, and the technology arguably more sophisticated.

The distinction worth noting is that Zinzino’s proof mechanism is embedded into the customer journey. The before-and-after retest is not optional or an upsell. It is the product experience. A Zinzino customer who retests and sees their omega-6 to omega-3 ratio improve has tangible, documented evidence sitting in their inbox. That evidence is generated by an independent lab and belongs to the customer.

Whether Herbalife’s newly acquired technology will deliver the same kind of independent, customer-held proof of results remains to be seen. The pieces are in place. The execution is what will determine whether it becomes a genuine science-backed customer experience or a more sophisticated version of the same personalized-sounding marketing the supplement industry has always produced.

The Numbers Tell a Story

The business results from both companies provide useful context.

Zinzino’s revenue for the full year 2025 reached SEK 3.3 billion, representing 51% growth over 2024, which itself grew 25% over the prior year. EBITDA margins improved to 13.3%. North America, historically Zinzino’s weakest region, grew 172% in 2025 driven by a series of strategic acquisitions including It Works!, Truvy, Bodē Pro, Valentus, Zurvita, and others. Each of these acquisitions follows a consistent integration strategy: absorb the distributor network, evaluate the product portfolio, and fold the best products into Zinzino’s test-based nutrition framework.

Zinzino is growing fast and doing so while maintaining profitability. That combination is unusual in direct selling.

Herbalife is operating in a more challenging position. The company remains under an FTC consent order and has faced persistent distributor retention and revenue pressure over recent years. The acquisitions represent a genuine strategic pivot, not just marketing. But Herbalife is essentially paying for a playbook that Zinzino wrote over fourteen years and has now proven at scale.

What This Means for Distributors and the Industry

For anyone building a health and wellness network marketing business right now, the convergence of these two companies on the same model is the clearest possible market signal.

The future of selling nutrition products through direct sales is not going to be built on product claims. It is going to be built on proof. Customers want to know that what they are taking is doing something measurable in their body. Independent testing, before-and-after data, and documented results are moving from a differentiator to a baseline expectation.

Zinzino has spent fourteen years building the infrastructure, the database, and the distributor education system to deliver that proof. Its growth numbers suggest the market is rewarding the model.

Herbalife has the global manufacturing scale, the distributor network in over 90 markets, and now the technology to build toward the same destination. The acquisitions of Pro2col, Link BioSciences, and Bioniq give it the raw ingredients. The integration, the training, and the customer experience design will determine whether those ingredients become something as defensible as what Zinzino has already built.

The health and wellness network marketing companies that are still selling one-size-fits-all products without a testing or proof component are watching both of these companies converge on a model that makes generic nutrition increasingly hard to justify. That pressure is only going to increase.

For distributors in either company, the single most important question is the same: can you show your customer documented proof that your products are working in their specific body?

If the answer is yes, you have a business conversation that almost nobody else in this industry can have.

If the answer is no, the window to change that is closing.

Talk soon,
Ty Tribble